Dementia Treatment Market - Snapshot

The dementia associated with Alzheimer’s disease market is expected to reach a market value of about US$ 6,936.8 Mn by the end of 2026, expanding at a single digit CAGR during the forecast period. Rise in R&D expenditure, increased prevalence of Alzheimer’s across the globe, increased geriatric population, rise in awareness regarding neurodegenerative diseases in developing countries, and rich pipeline of innovative treatment options are expected to boost the dementia associated with Alzheimer’s disease market during the forecast period. Moreover, increasing research and development activities in disease modifying drugs and surge in investment by key players in the clinical studies of advanced treatment options are expected to propel the dementia associated with Alzheimer’s disease market during the forecast period. However, the high cost of advanced treatments and severe side-effects associated with certain treatments are expected to hamper the dementia associated with Alzheimer’s disease market.

global dementia associated with alzheimer's disease market

The global dementia associated with Alzheimer’s disease market has been segmented based on drug class and distribution channel. In terms of drug class, the global market has been classified into cholinergic/ cholinesterase (ChE) inhibitor, memantine, and combined drug (memantine & donepezil) and others. The cholinergic/ cholinesterase (ChE) inhibitor segment dominates the dementia associated with Alzheimer’s disease market, in terms of value, as it is first line of treatment for AD and most widely prescribed drug for the treatment of AD. This segment is also expected to expand at a significant CAGR, owing to its effectiveness in the treatment of mild to severe dementia. Currently, there is no disease modifying treatment available for Alzheimer’s, and the only approved treatment for the symptomatic relief of AD are cholinesterase inhibitors (Aricept, and memantine. The memantine segment is expected to expand at a notable CAGR, owing to its ability to treat moderate to severe AD and its suitability in cholinergic/ cholinesterase (chE) inhibitors intolerant patients suffering from AD.

In terms of distribution channel, the dementia associated with Alzheimer’s disease market has been segregated into hospital pharmacies, retail, and online sales. The hospital pharmacies segment held a major share of the market in 2017, followed by retail. The hospital pharmacies segment is expected to maintain its market share during forecast period due to availability of cost-effective medications for the treatment of AD. The online pharmacies segment is projected to expand at a considerable CAGR during the forecast period, owing to easy availability of drugs at home at a discounted price and long-term treatment required for the treatment of Alzheimer’s disease.

In terms of geography, the dementia associated with Alzheimer’s disease market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America dominates the dementia associated with Alzheimer’s disease market owing to high awareness regarding Alzheimer’s disease in the U.S. and increased prevalence of AD in the region. According to the World Alzheimer’s Report, Alzheimer’s is the sixth-leading cause of death in the U.S. and currently, more than 5 million Americans are living with Alzheimer’s. Rising incidence of Alzheimer’s in elderly age group and demand for advanced therapies and disease modifying drugs is a major factor driving the market in North America. The market in Asia Pacific is projected to expand at a significantly high CAGR during the forecast period, owing to improving health care infrastructure and rising awareness regarding Alzheimer’s in countries such as China and India.

Major players operating in the dementia associated with Alzheimer’s disease market include Merz Pharma GmbH & Co. KGaA., Novartis AG, Allergan plc., Pfizer, Inc., Daiichi Sankyo Company, Limited, Ono Pharmaceutical Co., Ltd, Johnson & Johnson Services, Inc., Eisai Co., Ltd., H. Lundbeck A/S, and F. Hoffmann-La Roche Ltd. Key players are expanding their product portfolios through mergers & acquisitions and partnerships & collaborations with leading pharmaceutical and biotechnology companies and by offering technologically advanced products.

Dementia Treatment Market - Overview

This report analyzes the current and future scenario of the global dementia associated with Alzheimer’s disease market for the period 2018 to 2026. Rise in geriatric population, increased prevalence of Alzheimer’s, high unmet medical needs, and rich pipeline are likely to be major drivers of the global dementia associated with Alzheimer’s disease market during the forecast period.

The dementia associated with Alzheimer’s disease market report comprises an elaborate executive summary, including a snapshot that provides information on various segments of the market. It also provides information and data analysis of the global market with respect to segments based on drug class, distribution channel, and region. A detailed qualitative analysis of drivers, restraints, and opportunities of the market has been provided in the market overview section. Additionally, the section comprises competitive matrix and profiles of key market players, along with business overview, to project the competitive landscape of the market. The section also provides market attractiveness analysis based on region and market share analysis in terms of key players, thereby presenting a thorough analysis of the overall competitive scenario in the dementia associated with Alzheimer’s disease market.

Dementia Associated with Alzheimer’s Disease Market: Key Segments

Based on drug class, the global dementia associated with Alzheimer’s disease market has been segmented into cholinergic/ cholinesterase (ChE) inhibitors, memantine, and combined drug (memantine & donepezil) and others. The segments have been analyzed based on available drugs used during the treatment of AD and cost-effectiveness. In terms of distribution channel, the global dementia associated with Alzheimer’s disease market has been divided into hospital pharmacies, retail, and online sales. Based on market size and forecast for each of these segments have been provided for the period 2018 to 2026, along with their respective CAGR for the forecast period 2016 to 2026, considering 2017 as the base year.

Dementia Associated with Alzheimer’s Disease Market: Regional Outlook

In terms of region, the global dementia associated with Alzheimer’s disease market has been segmented into five major regions: North America (the U.S. and Canada), Europe (the U.K., Germany, France, Spain, Italy, and Rest of Europe), Asia Pacific (India, China, Japan, Australia & New Zealand, and Rest of Asia Pacific), Latin America (Brazil, Mexico, and Rest of Latin America), and Middle East & Africa (South Africa, GCC Countries, and Rest of Middle East & Africa). Market size and forecast for each of these regions and the mentioned countries have been provided for the period 2018 to 2026, along with their respective CAGR for the forecast period 2016 to 2026, considering 2017 as the base year. The research study also covers the competitive scenario in these regions.

Companies Mentioned in the Report

The report also profiles major players operating in the global dementia associated with Alzheimer’s disease market based on various attributes, such as company overview, financial overview, product portfolio, business strategies, and recent developments. The players covered in the report include Merz Pharma GmbH & Co. KGaA., Novartis AG, Allergan plc. Pfizer, Inc., Daiichi Sankyo Company, Limited, Ono Pharmaceutical Co., Ltd, Johnson & Johnson Services, Inc., Eisai Co., Ltd., H. Lundbeck A/S, and  F. Hoffmann-La Roche Ltd.

The global dementia associated with Alzheimer’s disease market has been segmented as below:

Drug Class

  • Cholinergic/ Cholinesterase (ChE) Inhibitors
  • Memantine
  • Combined Drug (Memantine & Donepezil) and Others
  •  

Distribution Channel

  • Hospital Pharmacies
  • Retail
  • Online Sales
  •  

Region

  • North America
    • U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific
    • India
    • China
    • Japan
    • Australia & New Zealand
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • South Africa
    • GCC Countries
    • Rest of Middle East & Africa

Custom Market Research Services

TMR offers custom market research services that help clients to get information on their business scenario required where syndicated solutions are not enough.

REQUEST CUSTOMIZATION

Dementia Associated Alzheimers Disease Market

Buy Now